Latanoprost protects rat retinal ganglion cells from apoptosis in vitro and in vivo

Kanamori, Akira; Naka, Maiko; Fukuda, Masahide; Nakamura, Makoto; Negi, Akira

doi:10.1016/j.exer.2008.11.012

Cited by 38 publications

(23 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…We previously showed that an active metabolite of latanoprost, another wellknown PG-related anti-glaucoma agent, also rescued retinal neuroglial progenitor R28 cells from apoptosis at concentrations of 10μM or lower [16]. The other report using RGC-5 cells showed latanoprost also has a protective effect at the similar concentrations as the current findings [9].…”

Section: Discussionsupporting

confidence: 69%

“…We previously reported that latanoprost rescued retinal neuroglial progenitor R28 cells from serum deprivation-induced apoptosis and neurons and/ or glial cells in the rat inner retina from experimental diabetes-induced apoptosis, probably through p44/p42 MAPK activation [16]. Also, we recently demonstrated that topical instillation of latanoprost protects the RGC death after optic nerve damage [9].…”

Section: Introductionmentioning

confidence: 97%

See 1 more Smart Citation

Tafluprost protects rat retinal ganglion cells from apoptosis in vitro and in vivo

Kanamori

Naka

Fukuda

et al. 2009

Graefes Arch Clin Exp Ophthalmol

Self Cite

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 69%

Section: Introductionmentioning

confidence: 97%

Tafluprost protects rat retinal ganglion cells from apoptosis in vitro and in vivo

Kanamori

Naka

Fukuda

et al. 2009

Graefes Arch Clin Exp Ophthalmol

Self Cite

View full text Add to dashboard Cite

show abstract

“…70 An in vitro study found less Ca 2 + influx in RGCs when exposed to glutamate as well as less apoptotic cells when cotreated with tafluprost. 84 Tafluprost also reduced the number of apoptotic RGCs and increased the number of surviving RGCs after optic nerve crush in experimental rats. 84 The mechanism behind the potential neuroprotective capacity of prostaglandins is not fully understood.…”

Section: Topical Therapiesmentioning

confidence: 99%

“…84 Tafluprost also reduced the number of apoptotic RGCs and increased the number of surviving RGCs after optic nerve crush in experimental rats. 84 The mechanism behind the potential neuroprotective capacity of prostaglandins is not fully understood. The neuroprotective effect of latanoprost seems to be at least partially mediated by the pro-survival p44/p42 mitogen-activated protein kinase (MAPK).…”

Section: Topical Therapiesmentioning

confidence: 99%

“…The neuroprotective effect of latanoprost seems to be at least partially mediated by the pro-survival p44/p42 mitogen-activated protein kinase (MAPK). 84,85 In contrast, bimatoprost seems to prevent from RGC loss via the Akt pathway. Stimulation of the FP receptor by bimatoprost leads to activation of the PI3K/Akt pathway, which not only has a prosurvival effect but also initiates the proapoptotic Raf/MEK/ERK pathway.…”

Section: Topical Therapiesmentioning

confidence: 99%

See 1 more Smart Citation

Pharmacotherapy of Glaucoma

Schmidl

Schmetterer²,

Garhöfer³

et al. 2015

Journal of Ocular Pharmacology and Therapeutics

137

View full text Add to dashboard Cite

Glaucoma is a group of diseases involving the optic nerve and associated structures, which is characterized by progressive visual field loss and typical changes of the optic nerve head (ONH). The only known treatment of the disease is reduction of intraocular pressure (IOP), which has been shown to reduce glaucoma progression in a variety of large-scale clinical trials. Nowadays, a relatively wide array of topical antiglaucoma drugs is available, including prostaglandin analogues, carbonic anhydrase inhibitors, beta-receptor antagonists, adrenergic agonists, and parasympathomimetics. In clinical routine, this allows for individualized treatment taking risk factors, efficacy, and safety into account. A major challenge is related to adherence to therapy. Sustained release devices may help minimize this problem but are not yet available for clinical routine use. Another hope arises from non-IOP-related treatment concepts. In recent years, much knowledge has been gained regarding the molecular mechanisms that underlie the disease process in glaucoma. This also strengthens the hope that glaucoma therapy beyond IOP lowering will become available. Implementing this concept with clinical trials remains, however, a challenge.

show abstract

Principles of Ocular Pharmacology

Park

Ellis

Mueller

et al. 2016

Handbook of Experimental Pharmacology

View full text Add to dashboard Cite

Recently, in a poll by Research America, a significant number of individuals placed losing their eyesight as having the greatest impact on their lives more so than other conditions, such as limb loss or memory loss. When they were also asked to rank which is the worst disease that could happen to them, blindness was ranked first by African-Americans and second by Caucasians, Hispanics, and Asians. Therefore, understanding the mechanisms of disease progression in the eye is extremely important if we want to make a difference in people's lives. In addition, developing treatment programs for these various diseases that could affect our eyesight is also critical. One of the most effective treatments we have is in the development of specific drugs that can be used to target various components of the mechanisms that lead to ocular disease. Understanding basic principles of the pharmacology of the eye is important if one seeks to develop effective treatments. As our population ages, the incidence of devastating eye diseases increases. It has been estimated that more than 65 million people suffer from glaucoma worldwide (Quigley and Broman. Br J Ophthalmol 90:262-267, 2006). Add to this the debilitating eye diseases of age-related macular degeneration, diabetic retinopathy, and cataract, the number of people effected exceeds 100 million. This chapter focuses on ocular pharmacology with specific emphasis on basic principles and outlining where in the various ocular sites are drug targets currently in use with effective drugs but also on future drug targets.

show abstract

Latanoprost protects rat retinal ganglion cells from apoptosis in vitro and in vivo

Cited by 38 publications

References 28 publications

Tafluprost protects rat retinal ganglion cells from apoptosis in vitro and in vivo

Tafluprost protects rat retinal ganglion cells from apoptosis in vitro and in vivo

Pharmacotherapy of Glaucoma

Principles of Ocular Pharmacology

Contact Info

Product

Resources

About